Michael A. Dyer, PhD

Michael A. Dyer, Ph.D.

Chair
Department of Developmental Neurobiology
St. Jude Children's Research Hospital

Affiliated Professor
Department of Anatomy and Neurobiology


St. Jude Children's Research Hospital
DTRC Room D2038D
262 Danny Thomas Place, MS 324
Memphis, TN 38105-3678
Tel: (901) 595-2257
Fax: (901) 595-7641
Email: Michael A. Dyer

 

Education

  • PhD Institution: Harvard University, Cambridge, Massachusetts

Links

St. Jude Faculty - Michael A. Dyer

Research Interests

My laboratory studies the regulation of growth during neural development and disease. Cell division must be carefully regulated during brain development to ensure that the resulting tissue is the appropriate size and contains the correct proportion of each specialized cell type. If the precise balance of cell types were altered in the brain, then the different neurons and glia would not be able to work together to process information. Many of the genes that control growth during development are also involved in regulating cell division following brain injury or in certain degenerative processes. In addition, these genes are often mutated in cancer cells. Therefore, by studying the regulation of growth during development, we can learn about the cause and progression of a variety of diseases in the central nervous system. This may ultimately lead to the design of better treatments for neural injury, degeneration and cancer.

The retina is a specialized region of the central nervous system that receives and processes visual information. Like the rest of the central nervous system, injury, degeneration and cancer involve changes in the growth properties of retinal cells. We use a wide range of experimental approaches to study how cell division is controlled during retinal development and disease. Methods currently being used in the lab include genetically engineered mice, replication incompetent retroviral vectors suitable for in vivo studies, explant culture systems, microarray hybridization, and to extended our observations to human retinopathies we use normal and diseased human tissue and monkey samples. Experimental approaches that are under development include retinal physiology (ERG), electron microscopy, cell sorting, in vivo mouse models of retinoblastoma, and computational modeling of proliferation during development.

Representative Publications

  • Brady SW, Ma X, Bahrami A, Satas G, Wu G, Newman S, Rusch M, Putnam DK, Mulder HL, Yergeau DA, Edmonson MN, Easton J, Alexandrov LB, Chen X, Mardis ER, Wilson RK, Downing JR, Pappo AS, Raphael BJ, Dyer MA, Zhang J. The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. Mol Cancer Res. 2019 Apr;17(4):895-906. doi: 10.1158/1541-7786.MCR-18-0620. Epub 2019 Jan 16. PubMed PMID: 30651371.
  • Shah NK, Qureshi MM, Dyer MA, Patel SA, Kim K, Everett PC, Grillone GA, Jalisi SM, Truong MT. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. Laryngoscope. 2019 Jan 9. doi: 10.1002/lary.27771. [Epub ahead of print] PubMed PMID: 30628077.
  • Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019 Mar 21;133(12):1313-1324. doi: 10.1182/blood-2018-09-871418. Epub 2019 Jan 7. PubMed PMID: 30617194; PubMed Central PMCID: PMC6428665.
  • Beckett RD, Stump CD, Dyer MA. Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions. J Med Libr Assoc. 2019 Jan;107(1):62-71. doi: 10.5195/jmla.2019.549. Epub 2019 Jan 1. PubMed PMID: 30598650; PubMed Central PMCID: PMC6300238.
  • Loh AHP, Stewart E, Bradley CL, Chen X, Daryani V, Stewart CF, Calabrese C, Funk A, Miller G, Karlstrom A, Krafcik F, Goshorn DR, Vogel P, Bahrami A, Shelat A, Dyer MA. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Lett. 2019 Feb 1;442:262-270. doi: 10.1016/j.canlet.2018.10.033. Epub 2018 Nov 3. PubMed PMID: 30395907; PubMed Central PMCID: PMC6342199.
  • Stewart E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M, Gordon B, Dapper J, Blankenship K, Yang Y, Li Y, Shaw TI, Cho JH, Wang X, Xu B, Gupta P, Fan Y, Liu Y, Rusch M, Griffiths L, Jeon J, Freeman BB 3rd, Clay MR, Pappo A, Easton J, Shurtleff S, Shelat A, Zhou X, Boggs K, Mulder H, Yergeau D, Bahrami A, Mardis ER, Wilson RK, Zhang J, Peng J, Downing JR, Dyer MA; St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell. 2018 Sep 10;34(3):411-426.e19. doi: 10.1016/j.ccell.2018.07.012. Epub 2018 Aug 23. PubMed PMID: 30146332; PubMed Central PMCID: PMC6158019.

View more references (pubmed link)